BCM
ACTU

Bridgeway Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Bridgeway Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.9K Sell
23,482
-7,500
-24% -$17.4K ﹤0.01% 1215
2026
Q1 		$84.9K Hold
30,982
– – ﹤0.01% 1139
2025
Q4 		$190K Buy
+30,982
New +$213K ﹤0.01% 1030

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Bridgeway Capital Management's ACTU Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Actuate Therapeutics (ACTU) stake by 24% in Q2 2026, selling an estimated $17.4K and leaving 23,482 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

Bridgeway Capital Management first reported a position in ACTU in Q4 2025 and has held it in 3 quarters since. The position peaked at $190K in Q4 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Bridgeway Capital Management held 23,482 shares of Actuate Therapeutics worth $35.9K as of Q2 2026.
  • Bridgeway Capital Management sold 7,500 Actuate Therapeutics shares in Q2 2026, an estimated $17.4K.
  • Actuate Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1215 holding.
  • Bridgeway Capital Management first reported a position in Actuate Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Bridgeway Capital Management's Actuate Therapeutics position peaked at $190K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.